Evidence map›Paper›PMID 20663687›Full record

ReviewTrends in endocrinology and metabolism: TEM2010

The proliferating role of insulin and insulin-like growth factors in cancer.

Emily Jane Gallagher, Derek LeRoith

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03813381 (The Impact of a Moderate CAlorie and Protein REstriction PROgram), which is not on this map. Cited by 195 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 9 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03813381 nacompletednot on this mapstarted 2015, after this paper: background citation

The Impact of a Moderate CAlorie and Protein REstriction PROgram (CARE-PRO) as an Efficient and Affordable Therapeutic Strategy in Patients With Barrett's Esophagus.

TypeinterventionalSponsorIstituto Oncologico Veneto IRCCSRan2015 to 2021Enrolled160ConditionsBarrett's Esophagus, Overweight and ObesityArmsCalorie and protein restriction diet
3 · Its place in the literature

Who cites it

195 citing papers in PubMed, 9 syntheses or guidelines pooled it, 366 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

135 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emily Jane GallagherDivision of Endocrinology, Diabetes and Bone Diseases, Mount Sinai School of Medicine, Box No. 1055, One Gustave L. Levy Place, New York, NY 10029, USA.
Derek LeRoith
Icahn School of Medicine at Mount Sinai · US

Funding

Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancerR01CA128799 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEROITH, DEREK · 2008 to 2018
$3.7M
NCI NIH HHS R01 CA128799
6 · The paper itself

Abstract

Epidemiological studies have reported an increased risk of cancer in people with type 2 diabetes (T2DM) and obesity, related in part to hyperinsulinemia, secondary to insulin resistance. Hyperinsulinemia leads to increased expression of insulin-like growth factor (IGF)-I expression. In fact, increased insulin, IGF-I and IGF-II levels are associated with tumor growth in vitro, in animal models, and in epidemiological studies in humans. In this paper, we discuss the roles of insulin, IGF-I and IGF-II, their interaction with the insulin receptor (IR) and IGF-I receptor (IGF-IR), and their signaling pathways and regulation as these pertain to tumor growth. We explain how these pathways have been deciphered by in vitro and in vivo studies, and how they are being exploited in the development of targeted cancer therapies.

Indexed as

AnimalsHumansInsulinInsulin-Like Growth Factor IInsulin-Like Growth Factor IINeoplasmsReceptor, IGF Type 1Receptor, InsulinSomatomedinsInsulinInsulin-Like Growth Factor IInsulin-Like Growth Factor IIReceptor, IGF Type 1Receptor, InsulinSomatomedins

Identifiers

PMID20663687
PMCPMC2949481
OpenAlexW1993248218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.